Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy

AIDS Reviews

Volumn 14, Issue 2, 2012, Pages 112-123

  Domingo, Pere ^a   Estrada, Vicente ^b   López Aldeguer, José ^c   Villaroya, Francesc ^d   Martínez, Esteban ^e  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

Aesthetic surgery; Antiretroviral drugs; Fat mass indexes; HIV infection; Lipoatrophy; Lipohypertrophy

Indexed keywords

ABACAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GROWTH HORMONE; INDINAVIR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MONOCYTE CHEMOTACTIC PROTEIN 1; NEVIRAPINE; PIOGLITAZONE; PRAVASTATIN; RALTEGRAVIR; RESISTIN; RITONAVIR; ROSIGLITAZONE; SAQUINAVIR; STAVUDINE; TENOFOVIR; TESAMORELIN; TUMOR NECROSIS FACTOR ALPHA; URIDINE; ZIDOVUDINE;

ANXIETY; APOPTOSIS; ARTHRALGIA; BODY FAT DISTRIBUTION; BODY MASS; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA POLYMORPHISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; EDEMA; ETHNIC DIFFERENCE; GENE EXPRESSION; GENETIC RISK; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INJECTION SITE REACTION; LIPOATROPHY; LIPOHYPERTROPHY; LIPOSUCTION; LIPOTOXICITY; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PREVALENCE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; RISK FACTOR; SKIN CONDUCTANCE; SOCIAL ASPECT;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; FEMALE; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; QUALITY OF LIFE; RISK FACTORS; SURGERY, PLASTIC;

EID: 84862540791     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Reynolds N, Neidig J, Wu A, Gifford A, Holmes W. Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution. AIDS Care. 2006;18:663-73.
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-8.
3. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60.
4. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr. 2005;40:121-31.
5. Podzamczer D, Ferrer E, Martinez E, et al. How much fat loss is needed for lipoatrophy to become clinically evident? AIDS Res Hum Retroviruses. 2009;25:563-7.
6. Carr A, Emery S, Law M, Puls R, Lundgren J, Powderly W. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361:726-35.
7. Law M, Puls R, Cheng A, Cooper D, Carr A. Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults. Antivir Ther. 2006;11:179-86.
8. Nguyen A, Calmy A, Schiffer V, et al. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Med. 2008;9:142-50.
9. Cabrero E, Griffa L, Burgos A. Prevalence and impact of body physical changes in HIV patients treated with highly active antiretroviral therapy: results from a study on patient and physician perceptions. AIDS Patient Care STDS. 2010;24:5-13.
10. Grunfeld C, Saag M, Cofrancesco J, et al. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS. 2010;24:1717-26.
11. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2002;31:50-5.
12. Lichtenstein K, Delaney K, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr. 2003;32:48-56.
13. Tien P, Cole S, Williams C, et al. Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr. 2003;34:461-6.
14. Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003;4:293-301.
15. Mutimura E, Stewart A, Rheeder P, Crowther N. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46:451-5.
16. Mercier S, Gueye N, Cournil A, et al. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study. J Acquir Immune Defic Syndr. 2009;51:224-30.
17. Moyle G, Hu W, Yang R, et al. Body composition changes in treatmentnaïve patients treated with boosted protease inhibitors plus tenofovir/emtricitabine. Results from the Castle trial from 96 weeks. 12th European AIDS Conference November 11-14, 2009 Cologne, Germany 2009 [Abstract LBPS11/6].
18. McComsey G, Kitch D, Daar E, et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: A prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. 17th CROI, 2010, San Francisco [Abstract 106LB].
19. Rockstroh J, Lennox J, DeJesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53:807-16.
20. Arribas J, Pozniak A, Gallant J, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47:74-8.
21. Heath K, Hogg R, Singer J, Chan K, O'Shaughnessy M, Montaner J. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort. J Acquir Immune Defic Syndr. 2002;30:440-7.
22. Haubrich R, Riddler S, DiRienzo A, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23:1109-18.
23. Saves M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002;34:1396-405.
24. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis. 2000;31:1482-7.
25. Martinez E, Mocroft A, Garcia-Viejo M, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-8.
26. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS. 2002;16:2447-54.
27. Bogner J, Vielhauer V, Beckmann R, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001;27:237-44.
28. Mauss S, Corzillius M, Wolf E, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med. 2002;3:49-55.
29. Palacios R, Galindo M, Arranz J, et al. Cervical lipomatosis in HIV-infected patients: a case-control study. HIV Med. 2007;8:17-21.
30. Galli M, Cozzi-Lepri A, Ridolfo A, et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med. 2002;162:2621-8.
31. Valantin M, Flandre P, Kohtla S, et al. Fat tissue distribution changes in HIV-infected patients with viral suppression treated with DRV/r monotherapy vs 2 NRTI + DRV/r in the MONOI-ANRS 136 randomized trial: results at 48 weeks. 17th CROI San Francisco 2010 [Abstract 721].
32. McComsey G, Rightmire A, Wirtz V, Yang R, Mathew M, McGrath D. Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study. Clin Infect Dis. 2009;48:1323-6.
33. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr. 2007;44:139-47.
34. Lichtenstein K, Ward D, Moorman A, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15:1389-98.
35. Galli M, Ridolfo A, Adorni F, et al. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy. Antivir Ther. 2003;8:347-54.
36. Earthman C, Traughber D, Dobratz J, Howell W. Bioimpedance spectroscopy for clinical assessment of fluid distribution and body cell mass. Nutr Clin Pract. 2007;22:389-405.
37. Padilla S, Gallego J, Masia M, Ardoy F, Hernandez I, Gutierrez F. Ultrasonography and anthropometry for measuring regional body fat in HIV-infected patients. Curr HIV Res. 2007;5:459-66.
38. Martinez E, Milinkovic A, Bianchi L, Gatell J. Considerations about the value of sonography for the measurement of regional body fat. AIDS. 2006;20:465-6.
39. Smith D, Hudson J, Martin A, et al. Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy. HIV Clin Trials. 2003;4:45-9.
40. Bickel M, Eisen J, Stephan C, et al. A standardized, comprehensive magnetic resonance imaging protocol for rapid and precise quantification of HIV-1-associated lipodystrophy. HIV Med. 2007;8:413-19.
41. Fontdevila J, Berenguer J, Prades E, et al. Validation of a simple classification for facial lipoatrophy in HIV-infected adults. 9th International workshop on adverse drugs reactions and lipodistrophy in HIV In: Antivir Ther. 2007;12(Suppl 2):L-31 [Abstract 18].
42. Funk E, Brissett A, Friedman C, Bressler F. HIV-associated facial lipoatrophy: establishment of a validated grading scale. Laryngoscope. 2007;117:1349-53.
43. Kelly T, Wilson K, Heymsfield S. Dual energy X-Ray absorptiometry body composition reference values from NHANES. PLoS ONE. 2009;4:e7038.
44. Freitas P, Santos A, Carvalho D, et al. Fat mass ratio: an objective tool to define lipodystrophy in hiv-infected patients under antiretroviral therapy. J Clin Densitom. 2010;13:197-203.
45. Brown T, Xu X, John M, et al. Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the Multicenter AIDS Cohort Study. AIDS Res Ther. 2009;6:8.
46. Hirsch J, Batchelor B. Adipose tissue cellularity in human obesity. Clin Endocrinol Metab. 1976;5:299-311.
47. Vidal F, Gutierrez F, Gutierrez M, et al. Pharmacogenetics of adverse effects due to antiretroviral drugs. AIDS Rev. 2010;12:15-30.
48. Palella F, Cole S, Chmiel J, et al. Anthropometrics and examiner-reported body habitus abnormalities in the multicenter AIDS cohort study. Clin Infect Dis. 2004;38:903-7.
49. Villarroya J, Diaz-Delfin J, Hyink D, et al. HIV type-1 transgene expression in mice alters adipose tissue and adipokine levels: towards a rodent model of HIV type-1 lipodystrophy. Antivir Ther. 2010;15:1021-8.
50. Villarroya F, Domingo P, Giralt M. Lipodystrophy in HIV 1-infected patients: lessons for obesity research. Int J Obes (Lond). 2007;31:1763-76.
51. Giralt M, Domingo P, Guallar J, et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy. Antivir Ther. 2006;11:729-40.
52. Brinkman K, Smeitink J, Romijn J, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354:1112-15.
53. Sievers M, Walker U, Sevastianova K, et al. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy. J Infect Dis. 2009;200:252-62.
54. Diaz-Delfin J, Del Mar G, Gallego-Escuredo J, et al. Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral Res. 2011;91:112-19.
55. Caron-Debarle M, Lagathu C, Boccara F, Vigouroux C, Capeau J. HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med. 2010;16:218-29.
56. Domingo P, Matias-Guiu X, Pujol R, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS. 1999;13:2261-7.
57. Kim M, Leclercq P, Lanoy E, et al. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study. Antivir Ther. 2007;12:1273-83.
58. Guallar J, Cano-Soldado P, Aymerich I, et al. Altered expression of nucleoside transporter genes (SLC28 and SLC29) in adipose tissue from HIV-1-infected patients. Antivir Ther. 2007;12:853-63.
59. Lafontan M, Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol Sci. 2003;24:276-83.
60. Villarroya J, Gallego-Escuredo J, Domingo J, et al. Differential alterations of gene expression in visceral versus subcutaneous adipose tissue from HIV-1-infected, HAART-treated patients with lipodystrophy: a pilot study. Antivir Ther. 2010;13(Suppl 4):A15.
61. Guallar J, Gallego-Escuredo J, Domingo J, et al. Differential gene expression indicates that 'buffalo hump' is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy. AIDS. 2008;22:575-84.
62. Rodriguez de la Concepcion M, Yubero P, Domingo J, et al. Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes. Antivir Ther. 2005;10:515-26.
63. Moreno-Torres A, Domingo P, Pujol J, Blanco-Vaca F, Arroyo J, Sambeat M. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy. Antivir Ther. 2007;12:195-203.
64. Luzi L, Perseghin G, Tambussi G, et al. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am J Physiol Endocrinol Metab. 2003;284:E274-80.
65. Haugaard S, Andersen O, Volund A, et al. Beta-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Clin Endocrinol (Oxf). 2005;62:354-61.
66. Moyle G, Moutschen M, Martinez E, et al. Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection. AIDS Rev. 2010;12:3-14.
67. Freitas P, Carvalho D, Madureira A, et al. Carotid Intima-media thickness is increased in HIV-infected patients with clinical lipodystrophy. 11th European AIDS Conference/EACS, Madrid, Spain 2007 [Abstract 36].
68. Martinez E, RiCVih Study group. Clinically evident facial lipoatrophy is associated with a higher cardiovascular risk. Antivir Ther. 2007;12(Suppl 2):L40.
69. Marin A, Casado J, Aranzabal L, et al. Validation of a specific questionnaire on psychological and social repercussions of the lipodystrophy syndrome in HIV-infected patients. Qual Life Res. 2006;15:767-75.
70. Santos C, Felipe Y, Braga P, Ramos D, Lima R, Segurado A. Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. AIDS. 2005;19(Suppl 4):S14-21.
71. Guaraldi G, Luzi K, Murri R, et al. Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy. Antivir Ther. 2007;12:1059-65.
72. Kuk J, Saunders T, Davidson L, Ross R. Age-related changes in total and regional fat distribution. Ageing Res Rev. 2009;8:339-48.
73. Gallant J, Staszewski S, Pozniak A, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
74. Gallant J, DeJesus E, Arribas J, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-60.
75. van Wyk J, Domingo P, Fredrick L, et al. Body fat distribution changes after 96 weeks of therapy with lopinavir/ritonavir plus raltegravir compared with LPV/r plus tenofovir/emtricitabine in antiretroviral-naïve, HIV-1-infected subjects from the PROGRESS study. 13th European AIDS Conference, 2011, Belgrade, Serbia. [Abstract 148bis].
76. Asensi V, Rego C, Montes A, et al. IL-1beta (+3954C/T) polymorphism could protect human immunodeficiency virus (HIV)-infected patients on highly active antiretroviral treatment (HAART) against lipodystrophic syndrome. Genet Med. 2008;10:215-23.
77. Ranade K, Geese W, Noor M, et al. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS. 2008;22:1561-8.
78. Zanone P, Riva A, Nasi M, et al. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS. 2008;22:1769-78.
79. Leyes P, Martinez E, Forga M. Use of diet, nutritional supplements and exercise in HIV-infected patients receiving combination antiretroviral therapies: a systematic review. Antivir Ther. 2008;13:149-59.
80. Hadigan C. Dietary habits and their association with metabolic abnormalities in human immunodeficiency virus-related lipodystrophy. Clin Infect Dis. 2003;37(Suppl 2):S101-4.
81. Foisy M, Yakiwchuk E, Chiu I, Singh A. Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med. 2008;9:389-96.
82. Malita F, Karelis A, Toma E, Rabasa-Lhoret R. Effects of different types of exercise on body composition and fat distribution in HIV-infected patients: a brief review. Can J Appl Physiol. 2005;30:233-45.
83. Drechsler H, Powderly W. Switching effective antiretroviral therapy: a review. Clin Infect Dis. 2002;35:1219-30.
84. Hansen B, Haugaard S, Iversen J, Nielsen J, Andersen O. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review. Scand J Infect Dis. 2004;36:244-53.
85. John M, McKinnon E, James I, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr. 2003;33:29-33.
86. Milinkovic A, Martinez E, Lopez S, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther. 2007;12:407-15.
87. Martinez E, Visnegarwala F, Grund B, et al. The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters. AIDS. 2010;24:353-63.
88. Martinez E, Milinkovic A, Garcia F, et al. Greater limb fat increase with intermittent (relative to continuous) thymidine-sparing antiretroviral therapy in HIV-infected patients with lipoatrophy. Antivir Ther. 2008;13:A9.
89. Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288:207-15.
90. Tebas P, Zhang J, Yarasheski K, et al. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr. 2007;45:193-200.
91. Fisher M, Moyle G, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2009;51:562-8.
92. Martin A, Smith D, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004;18:1029-36.
93. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106-18.
94. Raboud J, Diong C, Carr A, et al. A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials. 2010;11:39-50.
95. Sheth S, Larson R. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis. 2010;10:183.
96. Sutinen J, Walker U, Sevastianova K, et al. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther. 2007;12:97-105.
97. Mallon P, Miller J, Kovacic J, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study. AIDS. 2006;20:1003-10.
98. Calmy A, Bloch M, Wand H, et al. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial. HIV Med. 2010;11:493-501.
99. McComsey G, Walker U, Budhathoki C, et al. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229. AIDS. 2010;24:2507-15.
100. Guaraldi G, Fontdevilla J, Christensern L, et al. Surgical apporaches for correction of HIV-associated facial lipoatrophy. AIDS. 2011;25:1-11.
101. Fontdevila J, Serra-Renom J, Raigosa M, et al. Assessing the long-term viability of facial fat grafts: an objective measure using computed tomography. Aesthet Surg J. 2008;28:380-6.
102. Snel Y, Brummer R, Doerga M, et al. Adipose tissue assessed by magnetic resonance imaging in growth hormone-deficient adults: the effect of growth hormone replacement and a comparison with control subjects. Am J Clin Nutr. 1995;61:1290-4.
103. Rietschel P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab. 2001;86:504-10.
104. Kotler D, Muurahainen N, Grunfeld C, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;35:239-52.
105. Grunfeld C, Thompson M, Brown S, et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr. 2007;45:286-97.
106. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-70.
107. Johnson R. Reduction mammoplasty in an HIV-positive woman. AIDS Patient Care STDS. 2005;19:353-5.
108. Hultman C, McPhail L, Donaldson J, Wohl D. Surgical management of HIV-associated lipodystrophy: role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophy. Ann Plast Surg. 2007;58:255-63.
109. Nelson L, Stewart KJ. Plastic surgical options for HIV-associated lipodystrophy. J Plast Reconstr Aesthet Surg. 2008;61:359-65.
110. Moyle G, Sabin C, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043-50.
111. Lennox J, DeJesus E, Berger D, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010;55:39-48.
112. Maher B, Alfirevic A, Vilar F, Wilkins E, Park B, Pirmohamed M. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS. 2002;16:2013-18.
113. Nolan D, Moore C, Castley A, et al. Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS. 2003;17:121-3.
114. Tarr P, Taffe P, Bleiber G, et al. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis. 2005;191:1419-26.
115. Hulgan T, Tebas P, Canter J, et al. Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis. 2008;197:858-66.
116. Chiappini F, Teicher E, Saffroy R, Debuire B, Vittecoq D, Lemoine A. Relationship between polymerase gamma (POLG) polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients: a case-control study. Curr HIV Res. 2009;7:244-53.
117. Domingo P, Cabeza M, Pruvost A, et al. Association of thymidylate synthase gene polymorphisms with Stavudine triphosphate intracellular levels and lipodystrophy. Antimicrob Agents Chemother. 2011;55:1428-35.
118. Wangsomboonsiri W, Mahasirimongkol S, Chantarangsu S, et al. Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen. Clin Infect Dis. 2010;50:597-604.
119. Montes A, Valle-Garay E, Suarez-Zarracina T, et al. The MMP1 (-16071G/2G) single nucleotide polymorphism associates with the HAART-related lipodystrophic syndrome. AIDS. 2010;24:2499-506.